MX2020006840A - Composicion farmaceutica que comprende un peptido tipo apl. - Google Patents
Composicion farmaceutica que comprende un peptido tipo apl.Info
- Publication number
- MX2020006840A MX2020006840A MX2020006840A MX2020006840A MX2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A MX 2020006840 A MX2020006840 A MX 2020006840A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- apl peptide
- seq
- treatment
- relates
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 abstract 2
- 208000003456 Juvenile Arthritis Diseases 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010019668 Hepatic fibrosis Diseases 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 230000006329 citrullination Effects 0.000 abstract 1
- 235000013681 dietary sucrose Nutrition 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000000440 neutrophil Anatomy 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 239000007974 sodium acetate buffer Substances 0.000 abstract 1
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion provee una composicion farmaceutica que comprende el peptido tipo APL identificado como SEQ ID No. 1, el tampon acetato de sodio a pH 3,9 - 4,7; y al menos un azucar estabilizante seleccionado entre la sacarosa y la trehalosa; dicha composicion farmaceutica esutil para el tratamiento de las enfermedades inflamatorias relacionadas con un aumento de los neutrofilos o de la citrulinacion de proteinas; entre estas enfermedades inflamatorias se encuentran la artritis reumatoide (AR), la artritis idiopatica juvenil (AIJ), la espondilitis anquilosante (EA), la enfermedad de Alzheimer, y la fibrosis hepatica o pulmonar; la invencion tambien revela un métodopara el tratamiento de dichas enfermedades, mediante la administracion de una cantidad terapeuticamente efectiva de la composicion farmaceutica del peptido tipo APL identificado como SEQ ID No. 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2017000176A CU24508B1 (es) | 2017-12-29 | 2017-12-29 | Composición farmacéutica que comprende péptido tipo apl |
| PCT/CU2018/050007 WO2019129315A1 (es) | 2017-12-29 | 2018-12-21 | Composición farmaceutica que comprende un peptido tipo apl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020006840A true MX2020006840A (es) | 2020-09-03 |
Family
ID=65351834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020006840A MX2020006840A (es) | 2017-12-29 | 2018-12-21 | Composicion farmaceutica que comprende un peptido tipo apl. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200353040A1 (es) |
| EP (1) | EP3733196B1 (es) |
| JP (1) | JP7209000B2 (es) |
| KR (1) | KR102676701B1 (es) |
| CN (1) | CN111741763B (es) |
| AR (1) | AR114389A1 (es) |
| BR (1) | BR112020013033A2 (es) |
| CU (1) | CU24508B1 (es) |
| ES (1) | ES2960415T3 (es) |
| MX (1) | MX2020006840A (es) |
| WO (1) | WO2019129315A1 (es) |
| ZA (1) | ZA202004658B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4013780A4 (en) * | 2019-08-14 | 2024-04-10 | The Regents Of The University Of California | CAR-T CELLS SPECIFIC FOR MODIFIED PROTEINS IN EXTRACELLULAR SPACES |
| CU24626B1 (es) | 2019-12-26 | 2022-11-07 | Centro Nac De Biopreparados | Composición farmacéutica a base de proteínas con actividad neuroprotectora, inmunomoduladora, antiinflamatoria y antimicrobiana |
| CU20200026A7 (es) * | 2020-04-13 | 2021-11-04 | Ct Ingenieria Genetica Biotecnologia | Péptido para el tratamiento del síndrome de la tormenta de citocinas |
| CN111870697B (zh) * | 2020-09-18 | 2022-09-09 | 山东鲁抗医药股份有限公司 | 糖类物质在提高apl型衍生肽稳定性中的应用和冻干组合物 |
| CN119855602A (zh) * | 2022-07-22 | 2025-04-18 | 遗传工程与生物技术中心 | 用于治疗与在载脂蛋白ai或运甲状腺素蛋白方面的受损相关的疾病的肽 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23504A1 (es) * | 2004-09-24 | 2010-04-13 | Ct Ingenieria Genetica Biotech | Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas |
| CA2649538C (en) * | 2006-04-21 | 2014-06-03 | Yatin Gokarn | Buffering agents for biopharmaceutical formulations |
| EP2231180B1 (en) | 2008-01-16 | 2016-08-17 | Ben-gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
| EP2294086B1 (en) * | 2008-06-04 | 2017-09-13 | ModiQuest B.V. | Anti-inflammatory agents |
| CU23701A1 (es) * | 2008-12-29 | 2011-09-21 | Ct Ingenieria Genetica Biotech | Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i |
-
2017
- 2017-12-29 CU CU2017000176A patent/CU24508B1/es unknown
-
2018
- 2018-12-21 ES ES18845399T patent/ES2960415T3/es active Active
- 2018-12-21 JP JP2020536159A patent/JP7209000B2/ja active Active
- 2018-12-21 KR KR1020207021876A patent/KR102676701B1/ko active Active
- 2018-12-21 MX MX2020006840A patent/MX2020006840A/es unknown
- 2018-12-21 BR BR112020013033-8A patent/BR112020013033A2/pt not_active Application Discontinuation
- 2018-12-21 CN CN201880090158.9A patent/CN111741763B/zh active Active
- 2018-12-21 AR ARP180103792A patent/AR114389A1/es unknown
- 2018-12-21 US US16/958,586 patent/US20200353040A1/en not_active Abandoned
- 2018-12-21 EP EP18845399.7A patent/EP3733196B1/en active Active
- 2018-12-21 WO PCT/CU2018/050007 patent/WO2019129315A1/es not_active Ceased
-
2020
- 2020-07-28 ZA ZA2020/04658A patent/ZA202004658B/en unknown
-
2023
- 2023-12-22 US US18/394,284 patent/US20240316147A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AR114389A1 (es) | 2020-09-02 |
| CN111741763A (zh) | 2020-10-02 |
| EP3733196A1 (en) | 2020-11-04 |
| KR102676701B1 (ko) | 2024-06-20 |
| RU2020124953A3 (es) | 2022-01-31 |
| JP7209000B2 (ja) | 2023-01-19 |
| CN111741763B (zh) | 2024-06-14 |
| CU20170176A7 (es) | 2019-08-06 |
| US20240316147A1 (en) | 2024-09-26 |
| EP3733196B1 (en) | 2023-08-30 |
| CA3086280A1 (en) | 2019-07-04 |
| BR112020013033A2 (pt) | 2020-12-01 |
| CU24508B1 (es) | 2021-04-07 |
| US20200353040A1 (en) | 2020-11-12 |
| ZA202004658B (en) | 2022-01-26 |
| WO2019129315A1 (es) | 2019-07-04 |
| ES2960415T3 (es) | 2024-03-04 |
| JP2021508711A (ja) | 2021-03-11 |
| KR20200105869A (ko) | 2020-09-09 |
| RU2020124953A (ru) | 2022-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| EA202192588A1 (ru) | Фармацевтическая композиция, включающая вариант ph20 гиалуронидазы человека, и лекарственное средство для подкожного введения | |
| NZ725360A (en) | Liquid pharmaceutical composition | |
| PH12020551096A1 (en) | A modified raav capsid protein for gene therapy | |
| AR114389A1 (es) | Composición farmacéutica que comprende péptido tipo apl | |
| MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
| AU2017263237A1 (en) | GDF15 fusion proteins and uses thereof | |
| MX2020009000A (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil peptido. | |
| JP2017101068A5 (es) | ||
| JP2015517489A5 (es) | ||
| EA025267B1 (ru) | Водная фармацевтическая композиция этанерцепта, стабилизированная глутаматом | |
| JP2014221758A5 (es) | ||
| JP2017516848A5 (es) | ||
| PH12020551118A1 (en) | Modified lipidated relaxin b chain peptides and their therapeutic use | |
| HK1220611A1 (zh) | 用於治疗胃肠道病症的组成物 | |
| MX386387B (es) | Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona. | |
| JP2019501920A5 (es) | ||
| MX2020006822A (es) | Proteinas de fusion de anticuerpo de un solo dominio-citosina desaminasa. | |
| JP2015513318A5 (es) | ||
| BR112022002387A2 (pt) | Composto da fórmula z-y-q-y' ou um sal ou éster farmaceuticamente aceitável do mesmo | |
| JP2016513471A5 (es) | ||
| MX2018006269A (es) | Anticuerpo anti-alfa-v-integrina para el tratamiento de fibrosis y/o trastornos fibroticos. | |
| PE20210918A1 (es) | Composiciones y metodos para el tratamiento de la distrofia macular | |
| MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
| US20210046101A1 (en) | Combination therapeutics |